Collectively, these findings demonstrate that combining RTx, oHSV, and IGF1R inhibition synergistically enhances antitumor efficacy in GBM and BC, reduces the effective dose of each agent, and overcomes IGF1R-mediated resistance. Here, IGF1R is linked to breast cancer.